Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
Status:
Recruiting
Trial end date:
2022-07-06
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 study of zanubrutinib in Japanese participants with mature B-cell
malignancies.
This study intends to assess the use of zanubrutinib as an investigational agent to develop
new treatment options for Japanese participants with B-cell malignancies. No formal
hypothesis testing will be performed given the small sample size.